Clinical Research Directory
Browse clinical research sites, groups, and studies.
Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Summary
To evaluate the efficacy and toxicity of sodium glycididazole combined with concurrent chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer after neoadjuvant chemoradiotherapy.
Official title: Sodium Glycididazole Reduces Chemoradiotherapy-related Adverse Reactions During Concurrent Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-05-29
Completion Date
2026-07-20
Last Updated
2024-10-31
Healthy Volunteers
No
Conditions
Interventions
sodium glycididazole
Sodium glycididazole is intravenously infused at a dose of 800mg at 60 min before radiotherapy and used on Mondays, Wednesdays and Fridays during radiotherapy.
Locations (1)
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China